A Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Immune Thrombocytopenia A Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Immune Thrombocyto ...
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Persistent/Chronic Primary Immune Thrombocytopenia - / A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and ...
Safety and efficacy analysis of two conventional dosage regimens Methylprednisone for initial treatment of primary immune thrombocytopenia:A multicenter randomized controlled clinical trial Safety and efficacy analysis of two conventional dosage regimens Methylprednisone for initial treatm ...
Safety and efficacy analysis of two conventional dosage regimens Methylprednisone for initial treatment of primary immune thrombocytopenia:A multicenter randomized controlled clinical trial Safety and efficacy analysis of two conventional dosage regimens Methylprednisone for initial treatm ...
Primary immune thrombocytopenia
the short-course group (Group A):Oral methylprednisolone for 2 weeks, the initial dosage is 0.8mg/kg/d, than reduces to 0.4mg/kg/d for 1 week, than to 0.2mg/kg/d for 1 week, than stop.;the long-course treatment group (Group B):Oral methylprednisolone for 1 month, the initial dosage is 0.8mg/kg/d,than reduces to 0.4mg/kg/d for 1 month, than to 0.1mg/kg/d for 2 week, than stop.; the short-course group (Group A):Oral methylprednisolonefor 2 weeks, the initial dosage is 0.8mg/kg/ ...
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union ...
NULL
Pending
18
60
Both
the short-course group (Group A):150;the long-course treatment group (Group B):150;